Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatocellular Carcinoma
Gastric Cancer
Interventions
DRUG:
Nivolumab Injectable Product
COMBINATION_PRODUCT:
Trans-arterial tirapazamine embolization
Sponsor
Teclison Ltd.